Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Epidemiologic Notes and Reports Syrup of Ipecac Contamination

On April 29, the Food and Drug Administration (FDA) announced the nationwide recall of Humco-brand syrup of ipecac as a result of a labeling error. The manufacturer, Humco Laboratory, Inc., of Texarkana, Texas, undertook the recall of all lots of the product following a report to FDA from the Thrift Drug Company of Pittsburgh, Pennsylvania, that five of seven ipecac bottles in one of the company's drugstores had been found by the drug company to contain eucalyptus oil instead of ipecac. In addition to commercial sales, thousands of 1-ounce bottles of Humco-brand ipecac syrup were made available free to nonprofit organizations, including several poison control centers, throughout the United States during the week of May 2 as part of Poison Prevention Week campaigns.

The syrup was sold or given away as individual 1-ounce bottles or was included as part of a poison kit. At the time of the recall, 200,000 bottles were known to still be in distribution channels; another 200,000 bottles may already have reached consumers. FDA advises consumers to return all 1-ounce bottles labeled Humco ipecac. Reported by: Dallas District Office; Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration. Epidemiology Br, Div of Injury Epidemiology and Control, Center for Environmental Health and Injury Control, CDC. Editorial Note: Ipecac syrup is used mostly to induce vomiting in children under the age of 4 after a poisoning or suspected poisoning. Eucalyptus oil is commonly used in minute amounts in vaporizers and nose drops, and in cough drops as flavoring, and it is considered safe for these purposes. However, pure eucalyptus oil should never be ingested because even small amounts can quickly cause convulsions and coma. As little as 1 teaspoon (5 cc) can be fatal. Parents are urged to search for 1-ounce bottles of Humco ipecac and to return them to the source from which they were distributed.

For further information, contact Gust Koustenis, Recall Officer, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 7520 Standish Place, Rockville, Maryland 20855, telephone (301)295-8060.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #